Budget impact evaluation of the DAPA-HF trial: is dapagliflozin cost-saving for the treatment of heart failure with reduced ejection fraction?

L. Qin, O. Darlington,R. Miller, C. Mellstrom,P. Mcewan

EUROPEAN JOURNAL OF HEART FAILURE(2021)

引用 3|浏览7
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要